Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Complications

A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation

Bone Marrow Transplantation volume 30, pages 587–591 (2002)Cite this article

Abstract

Mucositis is a common and vexing complication of autologous progenitor cell transplantation (ABMT). A modified oral mucositis assessment scale (OMAS) has been found to be a reproducible and effective tool for monitoring mucositis after radiation therapy or chemotherapy. We utilized the modified OMAS scale to study clinical parameters associated with the development of mucositis in 79 patients undergoing ABMT. Median patient age was 52; 61% had non-Hodgkin's lymphoma (NHL), 23% multiple myeloma and 14% Hodgkin's disease. Patients were mobilized with G-CSF alone or the combination of etoposide plus G-CSF. Univariable correlates of worse mucositis were prior radiation therapy (P = 0.004), a diagnosis of NHL (P = 0.014), progenitor cell mobilizing regimen containing etoposide (P = 0.001), and ABMT preparative regimen containing etoposide (P = 0.006). Multivariable regression analysis revealed that NHL diagnosis (P = 0.007), prior radiation therapy (P = 0.001), and etoposide in the mobilizing regimen (P = 0.034) were associated with worse post-transplant mucositis. Worsening mucositis correlated with a longer inpatient length of stay. We conclude that several variables contribute to worsening mucositis during autologous transplantation, including etoposide in the progenitor cell mobilizing regimen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sonis S, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation J Clin Oncol 2001 19: 2201 2205

    Article  CAS  PubMed  Google Scholar 

  2. Rapoport A, Watelet L, Linder T et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants J Clin Oncol 1999 17: 2446 2453

    Article  CAS  PubMed  Google Scholar 

  3. Wardley A, Jayson G, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue Br J Haematol 2000 110: 292 299

    Article  CAS  PubMed  Google Scholar 

  4. Pillitteri LC, Clark RE . Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis Bone Marrow Transplant 1998 22: 495 498

    Article  CAS  PubMed  Google Scholar 

  5. Sonis S, Eilers J, Epstein J et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy Cancer 1999 85: 2103 2113

    Article  CAS  PubMed  Google Scholar 

  6. Reiser M, Josting A, Draube A et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization Bone Marrow Transplant 1999 23: 1223 1228

    Article  CAS  PubMed  Google Scholar 

  7. Kanfer EJ, McGuigan D, Samson D et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels Br J Cancer 1998 78: 928 932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Copelan E, Caselski S, Ezzone S et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease J Clin Oncol 1997 15: 759 765

    Article  CAS  PubMed  Google Scholar 

  9. Soni N, Meropol N, Pendyala L et al. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer J Clin Oncol 1997 15: 766 772

    Article  CAS  PubMed  Google Scholar 

  10. Postmus P, Mulder N, Sleijfer D et al. High-dose etoposide for refractory malignancies: a phase I study Cancer Treatment Rep 1984 68: 1471 1474

    CAS  Google Scholar 

  11. Copelan E, Penza S, Pohlman B et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma Bone Marrow Transplant 2000 25: 1243 1248

    Article  CAS  PubMed  Google Scholar 

  12. Kröger N, Hoffknecht M, Hänel M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy Bone Marrow Transplant 1998 21: 1171 1175

    Article  PubMed  Google Scholar 

  13. Zander A, Berger C, Kröger N et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission Clin Cancer Res 1997 3: 2671 2675

    CAS  PubMed  Google Scholar 

  14. Argiris A, Seropian S, Cooper D . High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease Ann Oncol 2000 11: 665 672

    Article  CAS  PubMed  Google Scholar 

  15. Chao N, Stein A, Long G et al. Busulfan/etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia Blood 1993 81: 319 323

    CAS  PubMed  Google Scholar 

  16. Postmus P, De Vries G, De Vries-Hospers H et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study Eur J Cancer Clin Oncol 1984 20: 777 782

    Article  CAS  PubMed  Google Scholar 

  17. Wolff S, Fer M, McKay C et al. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancy: a phase I study J Clin Oncol 1983 1: 701 705

    Article  CAS  PubMed  Google Scholar 

  18. Oblon DJ, Paul SR, Oblon MB et al. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation Bone Marrow Transplant 1997 20: 961 963

    Article  CAS  PubMed  Google Scholar 

  19. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study Bone Marrow Transplant 1996 17: 809 812

    CAS  PubMed  Google Scholar 

  20. Epstein JB, Vickars L, Spinelli et al. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation Oral Surg Oral Med Oral Pathol 1992 73: 682 689

    Article  CAS  PubMed  Google Scholar 

  21. Rutkauskas JS, Davis JW . Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report Oral Surg Oral Med Oral Pathol 1993 76: 441 448

    Article  CAS  PubMed  Google Scholar 

  22. Foote RL, Loprinzi CL, Frank AR et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis J Clin Oncol 1994 12: 2630 2633

    Article  CAS  PubMed  Google Scholar 

  23. Vesole D, Fuchs H . IB-367 Reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy Blood 1999 94: Abstr 675

    Google Scholar 

  24. Martin PJ, Hurd DD, Miller TR et al. A phase III randomized, placebo-controlled, double-blind, multinational study (RCDBM) of protegrin IB-67 rinse in reducing the incidence of ulcerative oral mucositis (OM) in patients (Pts) receiving stomatoxic chemotherapy (PROMPT-CT trial) Thirty-Seventh Ann Proc ASCO, May 2001 Abstr 1551

  25. Speilberger RT, Stiff P, Emmanouilides C et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 2 trial Thirty-Seventh Ann Proc ASCO, May 2001 Abstr 25

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    BJ Bolwell, M Kalaycio, R Sobecks, S Andresen, E Kuczkowski, L Bernhard, R Lomax, J Kohuth, S Mendiola, L Rybicki & B Pohlman

Authors
  1. BJ Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Andresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Kuczkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Bernhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Lomax
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Kohuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Mendiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolwell, B., Kalaycio, M., Sobecks, R. et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 30, 587–591 (2002). https://doi.org/10.1038/sj.bmt.1703694

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703694

Keywords

This article is cited by

Search

Advanced search

Quick links